Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Thematic Report: Geo-Economic Fragmentation; The Start of a Trade War?

Thematic Report: How Is International Trade Changing in the Coming Decade?

RBI Eases Repo-Rates: A Look at the Impact on the Indian Economy

The Beat Ideas: Strides Pharma~ A Growth Play Post OneSource Demerger

The Beat Ideas: Natco Pharma, The Cheapest Pharma Stock

The Beat Ideas: Globus Spirits- Maize, Capex, B2C Play

The Beat Ideas: EID Parry's Strategic Transformation- Cane to Consumer

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

India Pharmaceuticals / Thematic (Sector/Industry)

<ul>
<li>Highlight the potential windfall for Indian pharma due to Trump's "China Plus One" strategy. Emphasize how shifting US supply chains away from China could create significant opportunities for Indian manufacturers.  </li>
<li>Focus on Trump's conflicting goals of boosting domestic manufacturing while lowering drug costs. This inherent tension could benefit Indian generic companies as they offer affordable alternatives.  </li>
<li>Emphasize the uncertainty surrounding Trump 2.0's healthcare agenda. This ambiguity keeps investors on edge, creating an opportunity to present insightful analysis and predictions.</li>
</ul>


Highlight the potential windfall for Indian pharma due to Trump's "China Plus One" strategy. Emphasize how shifting US supply chains away from China could create significant opportunities for Indian manufacturers.  
Focus on Trump's conflicting goals of boosting domestic manufacturing while lowering drug costs. This inherent tension could benefit Indian generic companies as they offer affordable alternatives.  
Emphasize the uncertainty surrounding Trump 2.0's healthcare agenda. This ambiguity keeps investors on edge, creating an opportunity to present insightful analysis and predictions.


NSE Nifty Pharma Index (NSEPHRM INDEX EQUITY)

The Outlook of Indian Pharma Industry in Trump 2.0